Acute Myeloid Leukemia

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

Study results showed that CPI-613 did not improve survival in patients with metastatic adenocarcinoma of the pancreas.

An abundance of clinical trials is giving patients with acute myeloid leukemia (AML) hope for a better future.

Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.

“We are fortunate now to live in an era where we have nine new drugs approved (for AML) just in the last five years,” says an expert from The University of Texas MD Anderson Cancer Center.

“More and more (patients and physicians) need to work together in partnership throughout the cancer journey in order to optimize and make the journey the best possible that we can for every single patient,” says an expert from the Roswell Park Comprehensive Cancer Center.

A woman shares the story of her journey with multiple cancer types, including the same one that her mother died from.

Scientists have identified a potentially valuable genetic target in children with acute myeloid leukemia that could lead to further studies in immunotherapy drugs for the disease.

An analysis of more than 3.5 million children born between January 1996 and December 2016 demonstrated a stronger association between Down syndrome and acute myeloid leukemia risk than has been previously reported.

Treatment with a novel therapy as a single agent, or in combination with Venclexta, demonstrated a manageable safety profile and antileukemic effects in patients with relapsed/refractory acute myeloid leukemia. The study authors, however, note that more research is needed.

Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.

Patients with acute myeloid leukemia experience post-traumatic stress disorder symptoms including intrusion, avoidance and hypervigilance one month after diagnosis.

The agency granted approval to the revised label of Vyxeos to now include treatment for newly diagnosed therapy-related acute myeloid leukemia or disease with myelodysplasia-related changes in pediatric patients aged 1 and older.

Onureg, an oral form of the chemotherapy azacitidine, in older patients with acute myeloid leukemia who were in remission after chemotherapy contributed to longer survival outcomes, compared to placebo.

The FDA has lifted a partial clinical hold on a phase 2 trial evaluating a novel therapy in patients with acute myeloid leukemia following an allogenic stem cell transplant.

Here is a list of some recent trials that launched within the cancer space in December.

Here are the top 10 FDA oncology drug approvals that you may have missed this year.

A roundup of some of the most read news and updates in acute myeloid leukemia in 2020 from CURE®.

Here is a list of some recent trials that launched within the cancer space in November.

After granting accelerated approval in 2018, the Food and Drug Administration approved Venclexta in combination with Vidaza, Dacogen or low dose cytarabine in newly diagnosed patients with AML.

Adding Venclexta to Vidaza chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed.

The approval for patients with acute myeloid leukemia was based on data from the phase 3 QUAZAR AML-001 trial, which demonstrated that patients who received Onureg achieved a median overall survival of 24.7 months compared to 14.8 months for those who received placebo.

A roundup of the latest news and updates for patients with acute myeloid leukemia from CURE®.

The FDA’s fast track designation for BST-236 to treat adults aged 75 years or older with acute myeloid leukemia, or who have comorbidities that prevent the use of intensive induction chemotherapy, may open the doors to an accelerated approval.

A patient assessment tool, known as the Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu), was a viable and valid outcome measure for patients with acute myeloid leukemia not eligible for intensive therapy.

“Overall, the take-home point is that it's a small study so far and the follow-up time is still short, but it is pretty exciting preliminary data,” said Dr. Courtney DiNardo about the combination of Tibsovo plus Venclexta – with or without Vidaza – in IDH1-mutated acute myeloid leukemia.

The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute myeloid leukemia (AML).

The COVID-19 pandemic has created a unique challenge for patients with myelodysplastic syndromes and acute myeloid leukemia, creating many questions that experts tried to answer in a recent webinar from The Aplastic Anemia and MDS International Foundation.

The COVID-19 pandemic will continue to alter how patients with cancer receive their treatment, and experts within the United States who saw the virus strike early are offering their advice to other hospitals just starting to feel the effects.

Patients with acute myeloid leukemia whose disease has relapsed or become resistant to treatment saw a benefit with a combination of Opdivo and Vidaza.